Generic Name:fam-trastuzumab deruxtecan-nxki for injection Brand Name:Enhertu Drug Class:,Antineoplastic Topoisomerase Inhibitors,Antineoplastics, Anti-HER2 Medical Editor:John P. Cunha, DO, FACOEPLast updated on RxList:4/12/2024 homedrugs a-z listenhertu (fam-trastuzumab deruxtecan-nxki for ...
Generic Name:fam-trastuzumab deruxtecan-nxki for injection Brand Name:Enhertu Drug Class:,Antineoplastic Topoisomerase Inhibitors,Antineoplastics, Anti-HER2 Medical Editor:John P. Cunha, DO, FACOEPLast updated on RxList:4/12/2024 homedrugs a-z listenhertu (fam-trastuzumab deruxtecan-nxki for ...
Trastuzumab deruxtecan is an antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. Brand Names Enhertu Generic Name Trastuzumab deruxtecan DrugBank Accession Number DB14962 Background Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomeras...
“We are pleased that the FDA has accepted the application and granted Priority Review, as we believe trastuzumab deruxtecan has the potential to redefine the treatment of patients with HER2-positive metastatic breast cancer. Following the recent regulatory submission in Japan, we look forward to...
Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Trastuzumab is combined with Trastuzumab deruxtecan. Trastuzumab emtansine The risk or severity of neutropenia can be increased when Trastuzumab is combined with Trastuzumab emtansine. Tremelimumab The risk or severity ...
Before February 2023, there were up to six entities of biological agents (pertuzumab, trastuzumab emtansine, inetetamab, disitamab vedotin, trastuzumab deruxtecan, and margetuximab) on the market with indications for HER2-positive breast cancer and gastric cancer, akin to trastuzumab. Among these...
直至新型ADC药物 fam-trastuzumab deruxtecan-nxki(Enhertu,此前称为T-DXd或DS-8201a)的问世,打破了只有HER2阳性乳腺癌才能从抗HER2靶向治疗中获益的传统认知,HER2低表达的精准治疗时代来临。 ▲ADC药物Enhertu的作用机制:Enhertu与肿瘤细胞表面的HER2蛋白(浅绿色)结合,然后通过细胞内吞作用进入细胞内,随后药物的...
Daiichi Sankyo Inc. Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Prescribing Information. Basking Ridge, NJ: Daiichi Sankyo; revised April 2024. Keown A. Enhertu snags FDA approval for HER2-positive gastric cancer patients. BioSpace, January 18, 2021. Available...
Fam-trastuzumab deruxtecan-nxki powder for injection must be reconstituted and diluted prior to administration.Unopened vials of fam-trastuzumab deruxtecan-nxki injection should be stored at 2–8°C in the original carton for protection from light; vials should not be frozen....
DS-8201a的适应症是接受内分泌治疗转移性疾病后出现疾病进展的人表皮生长因子受体2低表达、激素受体阳性的晚期或转移性乳腺癌 此药物由Daiichi Sankyo, Inc./ Baxter Oncology GmbH/ 阿斯利康投资(中国)有限公司生产并提出实验申请,[实验的目的] 在HR+且HER2低表达(IHC 2+/ISH-和IHC 1+)人群中,根据BICR评估的PF...